What are the essential sectors of genetic testing where the Company expects Transrenal DNA platform will be the approach of choice?
The major sectors in which Transrenal DNA testing would be the method of choice are areas of molecular diagnostics based on “alien” DNA analysis such as: prenatal testing where the Tr-DNA test can be performed as early as 6 weeks of pregnancy; early tumor diagnosis including detection of pre-neoplastic conditions, tumor monitoring and detection of metastatic disease, and assessment of anti-tumor therapies; monitoring of transplanted cells, tissues and organs; and detection of pathogens. Xenomics is keenly aware of the fact that there are a growing number of opportunities to develop applications and new markets for the Transrenal DNA technology, including traditional genetic profiling.
Related Questions
- Is it essential for a Times Private Treaties investee company to appoint a media planning & buying agency in addition to TPT?
- Why should an investor approach the Stockbroker for purchase of shares instead of making direct contact with the company?
- What does being a Platform Manager at the Buell Motorcycle Company entail?
